Javier Carrillo
Family · San Antonio, TXNPI 1427417468
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Novo Nordisk at 32.3% of the total. 2025 is the largest year on record at $1,208, more than ten times the $17 reported in 2022.
Across 189 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$513
- Amgen$314
- Boehringer Ingelheim$156
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
- Esperion Therapeutics, Inc.$105
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,276100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $1,059 |
| Lilly USA, LLC | 38 | $513 |
| Amgen | 20 | $314 |
| Boehringer Ingelheim | 7 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $114 |
| Esperion Therapeutics, Inc. | 7 | $105 |
| AstraZeneca | 7 | $103 |
| Corcept Therapeutics | 5 | $101 |
| Bayer | 7 | $100 |
| Pfizer | 6 | $99 |
| Atland Pharmaceuticals, LLC | 1 | $82 |
| Lundbeck LLC | 4 | $72 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Shield Therapeutics Inc | 4 | $60 |
| Merck | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| AbbVie | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| GSK | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Biogen | 1 | $14 |
How this compares
$3,276 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $93,986 |
| JardianceEmpagliflozin | 20 | $27,415 |
| RybelsusSemaglutide | 18 | $27,367 |
| Repatha SureclickEvolocumab | 34 | $25,491 |
| JanuviaSitagliptin Phosphate | 17 | $20,713 |
| MounjaroTirzepatide | 17 | $18,847 |
| FarxigaDapagliflozin Propanediol | 12 | $17,126 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $7,301 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,189 |
| Atorvastatin Calcium | 191 | $1,187 |
| Levothyroxine Sodium | 126 | $1,012 |
| Losartan Potassium | 130 | $938 |
| Metoprolol Succinate | 71 | $902 |
| Chlorthalidone | 30 | $900 |
| Gabapentin | 55 | $855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,059 | $121,35381 claims |
| MerckJanuvia, Janumet Xr | $56 | $28,01330 claims |
| Boehringer IngelheimJardiance | $156 | $27,41520 claims |
| Lilly USA, LLCMounjaro | $513 | $18,84717 claims |
| AstraZenecaFarxiga | $103 | $17,12612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Febbie PhiriSan Antonio$31K
- Annette GantzSan Antonio$31K
- Renee ChisumSan Antonio$28K
- Thimios PartalasSan Antonio$27K
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.